Medpace Holdings, Inc. $MEDP Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 667,298 shares of the company’s stock after purchasing an additional 24,625 shares during the quarter. Geode Capital Management LLC’s holdings in Medpace were worth $374,836,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of MEDP. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the period. Sivia Capital Partners LLC acquired a new position in Medpace in the 2nd quarter worth approximately $296,000. Finally, M&T Bank Corp increased its holdings in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Insider Buying and Selling

In other news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MEDP shares. BMO Capital Markets cut their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price target for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Robert W. Baird cut their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Truist Financial cut their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada cut their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $467.08.

Medpace Stock Performance

Medpace stock opened at $447.11 on Monday. Medpace Holdings, Inc. has a 12 month low of $291.28 and a 12 month high of $628.92. The stock’s 50 day simple moving average is $457.47 and its two-hundred day simple moving average is $513.36. The firm has a market cap of $12.77 billion, a PE ratio of 28.10, a P/E/G ratio of 2.27 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the prior year, the firm posted $3.67 EPS. The business’s quarterly revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.